RxDoctor Payments Data

Kimberly Woyach

Nurse Practitioner · Mount Pleasant, WINPI 1174630057

Payments from drug & device makers

$755in general payments, 2019–2025

Across 12 payments — averaging $62.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$378
  • Averitas Pharma Inc.$118
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$109
  • Teva Pharmaceuticals USA, Inc.$97
  • Vanda Pharmaceuticals Inc.$22
  • Alkermes, Inc.$20
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$74498%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$755 in reported general payments places this provider in the 85th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$66,862
Medicare patients
142
Services billed
1,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide163$191,006
OzempicSemaglutide57$93,614
JardianceEmpagliflozin75$90,706
TrulicityDulaglutide50$61,660
XareltoRivaroxaban39$37,898
RybelsusSemaglutide15$29,505
JanuviaSitagliptin Phosphate26$29,411
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog27$24,470
LinzessLinaclotide32$24,212
EliquisApixaban11$18,951
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,828
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$11,764
Xigduo XrDapaglifloz Propaned/Metformin12$11,510
VyvanseLisdexamfetamine Dimesylate20$11,095
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$9,422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$12$252,666213 claims
Novo NordiskOzempic, Rybelsus$378$123,11972 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Mount Pleasant

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →